Related Experiment Video
Updated: Jul 2, 2025
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.9K
Understanding the Landscape of Clinically Available Molecular Testing
1Pathology and Diagnostic Medicine, Foundation Medicine, Inc 400 Summer Street, Boston, MA 02210, USA.
Surgical Oncology Clinics of North America
|February 24, 2024
Summary
Molecular testing in oncology has advanced significantly over 30 years, utilizing DNA, RNA, and protein assays. Understanding these tests is vital for personalized cancer care and selecting optimal diagnostic tools.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Diagnostics
Background:
- Cancer research advancements have driven the development of molecular assays.
- Molecular tests are increasingly used in routine clinical diagnostics.
Purpose of the Study:
- To highlight the evolution of molecular testing in oncology.
- To emphasize the importance of understanding molecular assay options for personalized medicine.
Main Methods:
- Review of advancements in DNA, RNA, and protein-based molecular assays.
- Analysis of the impact of molecular testing on cancer classification and treatment.
Main Results:
- Molecular tumor testing reveals limitations in current histopathologic classifications.
- New personalized treatment strategies are emerging based on molecular findings.
Conclusions:
- Awareness of molecular assay capabilities is crucial for oncologists.
- Optimal test selection enhances patient care and treatment efficacy.
Keywords:
Circulating tumor DNA (ctDNA)Immunohistochemistry (IHC)Liquid biopsyMolecular diagnosticsNext-generation sequencing (NGS)Precision oncologyTargeted therapyTumor biomarkers
